Many dividend investors may be overlooking Pfizer's stock, and that could be a costly mistake.

Newly filed engineering plans for the city’s largest office-to-housing conversion project show construction crews will gradually jack up sagging floors in increments of 1/64th of an inch, or roughly ...

Pfizer (PFE) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near ...

Pfizer's 5.8% yield looks tempting until you check what the dividend is actually costing the company relative to its cash ...

In the latest trading session, Pfizer (PFE) closed at $30.11, marking a +2.28% move from the previous day. The stock outperformed the S&P 500, which registered a daily gain of 0.28%. Meanwhile, the ...

This is a small sample size, of course, but it may be the start of a new trend emerging, with investors pivoting to safer ...

Pfizer is rated a Buy with new and acquired products generated $3.2B in Q2, growing 18% YoY and $13B annualized run-rate.

Pfizer is deeply unloved, and for good reason, but don't count this drug maker out just yet.

Ten consecutive earnings beats and a shrinking COVID hangover have Wall Street split on whether Pfizer deserves a breakout or a ceiling, and the answer hinges on a single pipeline deal that could ...

Pfizer Inc. (NYSE:PFE) has barely rewarded shareholders over the past year. That underperformance has left Pfizer looking ...

Pfizer (NYSE:PFE) agreed a research collaboration and licensing deal with Enodia Therapeutics to pursue Sec61-targeting small ...

Last week, drugmaker Pfizer (NYSE: PFE) declared a $0.43 fourth-quarter dividend, its 352nd consecutive quarterly dividend. The forward annual dividend, therefore, is $1.72 per share, which represents ...